Table 3.
Patient demographics and baseline characteristics
| Palonosetron arm | Granisetron arm | Total | |
|---|---|---|---|
| Chemotherapy | |||
| AP | 33 | 32 | 65 |
| IE or AI | 15 | 16 | 31 |
| Gender | |||
| Male | 7 | 5 | 12 |
| Female | 5 | 7 | 12 |
| Age | 36.1 (15–65) | 50.6 (18–70) | 43.4 (15–70) |
| ECOG performance status | |||
| 0 | 9 | 10 | 19 |
| 1 | 3 | 2 | 5 |
| 2 | 0 | 0 | 0 |
| Tumor type | 7 osteosarcoma | 4 MFH | |
| 4 MFH | 2 osteosarcoma | ||
| 1 synovial sarcoma | 2 leiomyosarcoma | ||
| 1 rhabdomyosarcoma | |||
| 1 DDLPS | |||
| 1 MYLPS | |||
| 1 clear cell sarcoma | |||
AI, ifosfamide plus doxorubicin; AP, cisplatin plus doxorubicin; DDLPS, dedifferentiated liposarcoma; ECOG, Eastern Cooperative Oncology Group; IE, ifosfamide plus etoposide; MFH, malignant fibrous histiocytoma; MYLPS, myxoid liposarcoma.